RxDoctor Payments DataLook up a doctor →

David Guillot, MD

Family Medicine · Oakdale, LANPI 1215939558

Payments from drug & device makers

$14,963in general payments, 2019–2025

Across 973 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • GSK$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$783
  • Merck$629
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$14,80699%
  • Education$1571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,963 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$25,033
Medicare patients
85
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide220$264,213
OzempicSemaglutide190$257,081
JardianceEmpagliflozin227$183,548
IngrezzaValbenazine Tosylate22$176,677
FarxigaDapagliflozin Propanediol214$144,255
LinzessLinaclotide202$130,116
TrulicityDulaglutide90$123,183
EliquisApixaban189$96,186
Tresiba Flextouch U-200Insulin Degludec50$72,457
XareltoRivaroxaban106$71,383
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$64,203
NuplazidPimavanserin Tartrate23$55,395
XifaxanRifaximin13$48,426
RexultiBrexpiprazole23$42,610
JanuviaSitagliptin Phosphate64$37,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$783$387,395310 claims
Novo NordiskOzempic$1,558$257,081190 claims
Boehringer IngelheimJardiance, Tradjenta$537$214,973298 claims
Neurocrine Biosciences, Inc.Ingrezza$51$176,67722 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,233$166,878265 claims
AbbVieLinzess, Vraylar, Ubrelvy$2,629$165,443230 claims
PfizerEliquis$571$96,186189 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,491$75,53380 claims
Johnson & JohnsonXarelto$34$71,383106 claims
Acadia Pharmaceuticals IncNuplazid$108$55,39523 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$219$48,42613 claims
Otsuka America Pharmaceutical, Inc.Rexulti$331$42,61023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Oakdale

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →